Search | Clinical Trials Finder

Conditions: Conduct Disorder, Oppositional Defiant Disorder
Interventions: L2B, L2B + App, skills for success; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 13 Years to 17 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Spinal Cord Injury
Interventions: D-Cycloserine, Placebo, Training, Stimulation, Placebo Stimulation; Drug · Other
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 18 Years to 85 Years
Enrollment: 257 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pterygium
Interventions: Bevacizumab, Mitomycin C; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 80 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Dental Caries
Interventions: C16G2; Drug
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Kalispell, Montana • Salt Lake City, Utah

Conditions: Critical Limb Ischemia
Interventions: Pneumatic calf compression, Filgrastim; Device · Drug
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 35 Years to 85 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Deep Partial or Full Thickness Wounds
Interventions: Fibrin Sealant, ARTISS 4IU/ml VH SD, Staples; Biological · Other
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: Up to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 17
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 14 more

Conditions: Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions: GM-CSF, Dendritic Cell/Tumor Fusion Vaccine, imiquimod; Drug · Biological
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2025
U.S. locations: 4
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma
Interventions: Isatuximab, Iberdomide, Bortezomib (B), Dexamethasone, Melphalan, Linvoseltamab, On Body Delivery System (OBDS); Drug · Device
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2038
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Myelodysplastic Syndrome Acute Myeloid Leukemia
Interventions: Nivolumab; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Effect of Test Articles on the Healing of a Wound Artificially Induced by Liquid Nitrogen Spray
Interventions: Fibrin, White Petrolatum; Biological · Other
Lead sponsor: Healthpoint; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Melanoma (Skin)
Interventions: resiquimod; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Skin Infection
Interventions: Medicinal honey, Bacitracin; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years to 100 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Novi, Michigan

Conditions: Melanoma, Metastatic Melanoma, Mucosal Melanoma
Interventions: Peptide Vaccine (LPV7) + Tetanus peptide, PolyICLC, Resiquimod, IFA; Biological · Other
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 2
States / cities: Houston, Texas • Charlottesville, Virginia

Conditions: Sarcoma, Sarcoma, Ewing, Desmoplastic Small Round Cell Tumor, Refractory Sarcoma, Osteosarcoma, Rhabdomyosarcoma
Interventions: PEEL-224, Temozolomide, Vincristine, Pegfilgrastim, Filgrastim; Drug · Biological
Lead sponsor: David S Shulman, MD; Other
Eligibility: 12 Years to 49 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Sarcoma
Interventions: dactinomycin, cyclophosphamide, etoposide, ifosfamide, vincristine sulfate, Conventional Surgery, MESNA (mercaptoethane sulfonate), Filgrastim; Biological · Drug · Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 2 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 64
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Downey, California + 57 more

Conditions: Cervical Cancer
Interventions: Bevacizumab, Carboplatin, Radiation Therapy; Drug · Radiation
Lead sponsor: Leo W. Jenkins Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Greenville, North Carolina

Conditions: NEUROFIBROMATOSIS 1
Interventions: aminolevulinic acid; Drug
Lead sponsor: Donald Basel; Other
Eligibility: 14 Years to 30 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Musculoskeletal Injury, Hypogonadism, Hormonal Contraception
Interventions: Goserelin 3.6 MG, Multi-Stressor Training, Testosterone gel (AndroGel 5g), Testosterone gel (AndroGel 1.25g); Drug · Other
Lead sponsor: Bradley Nindl; Other
Eligibility: 18 Years to 40 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethylene (ePTFE) Graft Prostheses
Interventions: Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), Surgical gauze pads; Biological · Other
Lead sponsor: Baxter Healthcare Corporation; Industry
Eligibility: Not listed
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 22
States / cities: Birmingham, Alabama • Tucson, Arizona • Fresno, California + 19 more

Conditions: Fractures, Open, Surgical Wound Infection
Interventions: Vancomycin; Drug
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Diabetic Foot Ulcers
Interventions: Santyl, Tegaderm Hydrogel; Drug
Lead sponsor: Healthpoint; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Venous Leg Ulcer
Interventions: Omeza® OCM™; Device
Lead sponsor: Omeza, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 7
States / cities: Los Angeles, California • Hollywood, Florida • North Port, Florida + 4 more

Conditions: Breast Cancer
Interventions: Reduced glutathione; Drug
Lead sponsor: Nathalie Johnson; Other
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Dental Caries
Interventions: C16G2, Placebo; Drug
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Kalispell, Montana

Search by objective public record fields.

Pathways 2 Success

Lower Limb Function After Spinal Cord Injury

Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery

Phase 2, Open-Label Study for Safety, Microbiology and PK of Single or Multiple Oral C16G2 Gel Doses

Proteomics and Stem Cell Therapy as a New Vascularization Strategy

Safety and Efficacy Study of FS 4 IU VH S/D (Fibrin Sealant With 4IU/mL Thrombin, Vapor Heated, Solvent/Detergent Treated) to Adhere Split Thickness Skin Grafts and Improve Wound Healing in Burn Patients

Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod

Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide

Study to Determine if Fibrin Affects the Ability of a Wound to Heal

Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery

The Use of Medical Grade Honey in the Prevention of Bone Anchored Hearing Aid Associated Skin Breakdown

Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma

Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer

Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II

Adaptions and Resiliency to Multi-Stressor OpeRations

FS VH S/D 500 S-apr in Vascular Surgery

Local Application of Vancomycin Powder in Grade I-IIIA Open Fractures

Enzymatic Versus (vs) Autolytic Debridement of Diabetic Foot Ulcers

Omeza Combination Therapy With Standard of Care to Standard of Care Alone for Chronic Venous Leg Ulcers

RayGel-An Alternative for Skin Care During External Beam Radiation

A Phase 2 Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Varnish and Strip in Adolescent and Adult Subjects